Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ensysce Biosciences (ENSC) Return on Sales (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Return on Sales for 6 consecutive years, with 7.6% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Sales fell 779.0% to 7.6% in Q3 2025 year-over-year; TTM through Sep 2025 was 2.46%, a 67.0% decrease, with the full-year FY2024 number at 1.54%, up 342.0% from a year prior.
  • Return on Sales was 7.6% for Q3 2025 at Ensysce Biosciences, down from 1.28% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.19% in Q3 2024 to a low of 33.94% in Q2 2022.
  • A 5-year average of 7.81% and a median of 6.24% in 2023 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: soared 5021bps in 2021, then plummeted -3097bps in 2022.
  • Ensysce Biosciences' Return on Sales stood at 1.29% in 2021, then plummeted by -234bps to 4.29% in 2022, then crashed by -58bps to 6.8% in 2023, then soared by 60bps to 2.75% in 2024, then crashed by -176bps to 7.6% in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Return on Sales are 7.6% (Q3 2025), 1.28% (Q2 2025), and 1.49% (Q1 2025).